TD Cowen lifts HCA Healthcare stock target to USD 460.00

Published on 10/20/2026 at 11:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

HCA posted USD 20.23 billion in the second quarter of 2026. HCA Healthcare stock costs EUR 406.10 on October 20, 2026 after EUR 412.40 on October 19, 2026.

Target revisions precede results

HCA Healthcare reported USD 20.23 billion in second-quarter 2026 revenue.
RBC Capital raised its target from USD 435.00 to USD 496.00 on October 7, 2026.
HCA Healthcare stock trades at EUR 406.10 at 11:02 a.m. CEST at Lang & Schwarz on October 20, 2026.
HCA Healthcare is scheduled to report third-quarter results on October 27, 2026.

Isometrische 3D-Illustration der Krankenhaus-Wertschöpfungskette: Aufnahme, Diagnose, OP, Pflege, Apotheke — HCA Healthcare US40412C1018 isometrisches Diagramm der Wertschöpfungskette vom Patienten über Diagnose bis zur Apotheke, Illustration mit AI erstellt.

HCA Healthcare stock (ISIN US40412C1018) is at EUR 406.10 at Lang & Schwarz on October 20, 2026, while TD Cowen raised its target from USD 431.00 to USD 460.00 on October 12, 2026, according to MarketBeat. The target revision puts the next quarterly report on October 27, 2026 at the center of the trading setup.

Three results shaped the story

On July 24, 2026, HCA reported second-quarter revenue of USD 20.23 billion, up 8.70 percent year over year, and earnings per share of USD 7.59 versus a USD 7.56 consensus estimate, according to MarketBeat. On October 7, 2026, RBC Capital lifted its target from USD 435.00 to USD 496.00 and retained an Outperform rating, as reported by Markets Insider. TD Cowen then raised its target to USD 460.00 from USD 431.00 on October 12, 2026, the third dated event in the sequence.

What does the target signal?

The October target changes show a split in the valuation picture rather than a single street view. RBC's USD 496.00 target is USD 61.00 above its former level, while TD Cowen's USD 460.00 target is USD 29.00 higher than its previous target. MarketBeat reported a consensus target of USD 467.61 from 24 analysts, with 16 Buy ratings, seven Holds and one Sell rating. The same report identified insurer reimbursement disputes as a risk for HCA's operating outlook.

When are the next dates?

HCA Healthcare is scheduled to release third-quarter 2026 results on October 27, 2026, with its earnings call at 10:00 a.m. Eastern time, according to the company's HCA Healthcare. The report will test whether the second-quarter revenue growth rate and earnings performance carried into the next period.

Stock price stays the market anchor

HCA Healthcare's latest reported quarter combined USD 20.23 billion in revenue with USD 1.93 billion in net income and diluted earnings per share of USD 7.62 for the second quarter of 2026. That operating base gives the October analyst revisions a measurable earnings context, while the October 27 reporting date provides the next scheduled catalyst.

HCA Healthcare was trading at EUR 406.10 at Lang & Schwarz on October 20, 2026 at 11:02 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of HCA Healthcare stock.